Mochida Pharmaceutical Co., Ltd. has set the offering price for common shares at JPY 3,331 per share, with a total offering amount of approximately JPY 3,842.64 million, and an overallotment portion of 173,000 shares totaling approximately JPY 576.26 million. The application period is April 7 to 8, 2026, with the settlement date on April 13.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4534-20260406-01.pdf","jir_short_summary":"Mochida Pharmaceutical Co., Ltd. has set the offering price for common shares at JPY 3,331 per share, with a total offering amount of approximately JPY 3,842.64 million, and an overallotment portion of 173,000 shares totaling approximately JPY 576.26 million. The application period is April 7 to 8, 2026, with the settlement date on April 13.","jir_summary":"### Summary of Capital Policy\nBased on the resolution of the Board of Directors on March 30, 2026, Mochida Pharmaceutical Co., Ltd. has determined the offering price for common shares at JPY 3,331 per share. The offering will be conducted through an underwriting purchase method, with a total offering price amounting to approximately JPY 3,842.64 million. The underwriting price is JPY 3,193.60 per share, totaling approximately JPY 3,684.14 million. An overallotment offering of 173,000 shares totaling approximately JPY 576.26 million will also be implemented. The application period is from April 7 to April 8, 2026, with settlement scheduled for April 13. The offering price is set at a 3.03% discount against the reference price of JPY 3,435 as of April 6, 2026.\n\n### Impact on Shareholders and Future Schedule\nThis offering will increase the number of shares available in the market, potentially diluting existing shareholders; however, the exact increase rate in shares is not specified in the document. The exercise period for the green shoe option is from April 13 to April 23, 2026, and the syndicate cover transaction period is from April 9 to April 23, 2026. Additional offerings may be conducted during these periods. Investors are advised to carefully review the share offering prospectus before making decisions.","jir_financial_highlights":"Offering Price: JPY 3,331 per share (Unknown)\nTotal Offering Amount: JPY 3,842,641,600 (Unknown)\nUnderwriting Price: JPY 3,193.60 per share (Unknown)\nTotal Underwriting Amount: JPY 3,684,136,960 (Unknown)\nOverallotment Offering Shares: 173,000 shares (Unknown)\nTotal Overallotment Offering Price: JPY 576,263,000 (Unknown)\nReference Date and Price: 2026-04-06 JPY 3,435 (Unknown)\nDiscount Rate: 3.03% (Unknown)","jir_category":"","jir_hashtags":"#MochidaPharmaceuticalCoLtd, #CapitalPolicy, #ShareOffering, #JapaneseStocks","jir_key_figures":"Offering Price: JPY 3,331 per share\nTotal Offering Amount: JPY 3,842,641,600\nOverallotment Offering Shares: 173,000 shares","jir_meta_title":"Mochida Pharmaceutical Co., Ltd. Determines Common Share Offering Price at JPY 3,331 per Share, Totaling Approximately JPY 3.8 Billion","jir_meta_description":"Mochida Pharmaceutical Co., Ltd. sets the offering price for common shares at JPY 3,331 per share, with a total offering amount of about JPY 3.8 billion and an overallotment portion of 173,000 shares around JPY 570 million. Application period is April 7 to 8, 2026; settlement date is April 13.","jir_og_title":"Mochida Pharmaceutical Announces Common Share Offering Price Determination (JPY 3,331 per Share)","jir_og_description":"Mochida Pharmaceutical Co., Ltd. has set the offering price for common shares at JPY 3,331 per share. The total offering amount is approximately JPY 3.8 billion. Application period is April 7 to 8, with settlement scheduled for April 13.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-39210","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n